JP2019512482A5 - - Google Patents

Download PDF

Info

Publication number
JP2019512482A5
JP2019512482A5 JP2018546618A JP2018546618A JP2019512482A5 JP 2019512482 A5 JP2019512482 A5 JP 2019512482A5 JP 2018546618 A JP2018546618 A JP 2018546618A JP 2018546618 A JP2018546618 A JP 2018546618A JP 2019512482 A5 JP2019512482 A5 JP 2019512482A5
Authority
JP
Japan
Prior art keywords
fluoro
phenyl
carboxamide
trifluoromethyl
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018546618A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512482A (ja
JP7624690B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2017/050269 external-priority patent/WO2017147700A1/en
Publication of JP2019512482A publication Critical patent/JP2019512482A/ja
Publication of JP2019512482A5 publication Critical patent/JP2019512482A5/ja
Priority to JP2022028700A priority Critical patent/JP2022071046A/ja
Priority to JP2024071190A priority patent/JP2024102151A/ja
Application granted granted Critical
Publication of JP7624690B2 publication Critical patent/JP7624690B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018546618A 2016-03-01 2017-03-01 Wdr5タンパク質-タンパク質結合の阻害剤 Active JP7624690B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022028700A JP2022071046A (ja) 2016-03-01 2022-02-25 Wdr5タンパク質-タンパク質結合の阻害剤
JP2024071190A JP2024102151A (ja) 2016-03-01 2024-04-25 Wdr5タンパク質-タンパク質結合の阻害剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662301673P 2016-03-01 2016-03-01
US62/301,673 2016-03-01
PCT/CA2017/050269 WO2017147700A1 (en) 2016-03-01 2017-03-01 Inhibitors of wdr5 protein-protein binding

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022028700A Division JP2022071046A (ja) 2016-03-01 2022-02-25 Wdr5タンパク質-タンパク質結合の阻害剤

Publications (3)

Publication Number Publication Date
JP2019512482A JP2019512482A (ja) 2019-05-16
JP2019512482A5 true JP2019512482A5 (https=) 2020-04-09
JP7624690B2 JP7624690B2 (ja) 2025-01-31

Family

ID=59743306

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018546618A Active JP7624690B2 (ja) 2016-03-01 2017-03-01 Wdr5タンパク質-タンパク質結合の阻害剤
JP2022028700A Pending JP2022071046A (ja) 2016-03-01 2022-02-25 Wdr5タンパク質-タンパク質結合の阻害剤
JP2024071190A Pending JP2024102151A (ja) 2016-03-01 2024-04-25 Wdr5タンパク質-タンパク質結合の阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022028700A Pending JP2022071046A (ja) 2016-03-01 2022-02-25 Wdr5タンパク質-タンパク質結合の阻害剤
JP2024071190A Pending JP2024102151A (ja) 2016-03-01 2024-04-25 Wdr5タンパク質-タンパク質結合の阻害剤

Country Status (17)

Country Link
US (2) US11319299B2 (https=)
EP (1) EP3423451B1 (https=)
JP (3) JP7624690B2 (https=)
KR (1) KR20180120720A (https=)
CN (1) CN109195965B (https=)
AU (1) AU2017226004B2 (https=)
BR (1) BR112018067392A2 (https=)
CA (1) CA3015406A1 (https=)
CL (1) CL2018002505A1 (https=)
CO (1) CO2018010504A2 (https=)
DK (1) DK3423451T3 (https=)
EA (1) EA038109B1 (https=)
EC (1) ECSP18073726A (https=)
IL (1) IL261472B (https=)
MX (1) MX2018010374A (https=)
WO (1) WO2017147700A1 (https=)
ZA (1) ZA201805879B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3015417A1 (en) 2016-03-01 2017-09-08 Propellon Therapeutics Inc. Inhibitors of wdr5 protein-protein binding
JP7624690B2 (ja) * 2016-03-01 2025-01-31 プロペロン セラピューティクス インコーポレイテッド Wdr5タンパク質-タンパク質結合の阻害剤
EP3532464A4 (en) 2016-10-28 2020-07-08 Icahn School of Medicine at Mount Sinai COMPOSITIONS AND METHODS FOR THE TREATMENT OF EZH2 MEDIATION CANCER
JP2020514252A (ja) 2016-12-08 2020-05-21 アイカーン スクール オブ メディスン アット マウント シナイ Cdk4/6媒介性がんを治療するための組成物および方法
PL3601233T3 (pl) 2017-03-27 2025-01-07 HYDRO-QUéBEC Sole do zastosowania w kompozycjach elektrolitowych lub jako dodatki do elektrod
MX2020002399A (es) * 2017-09-06 2020-07-22 Propellon Therapeutics Inc Inhibidores del enlace proteína-proteína de wdr5.
US10501466B2 (en) 2017-09-19 2019-12-10 Vanderbilt University WDR5 inhibitors and modulators
EP3736266A4 (en) * 2018-01-04 2021-01-06 Peking University Shenzhen Graduate School COMPOUND SIMULTANEOUSLY INHIBITING THE LSD1 AND HDAC TARGETS AND ITS APPLICATION
CA3092677A1 (en) 2018-03-06 2019-09-12 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (akt) degradation / disruption compounds and methods of use
CN108715585A (zh) * 2018-04-23 2018-10-30 中国药科大学 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂
US10844044B2 (en) 2018-06-14 2020-11-24 Vanderbilt University WDR5 inhibitors and modulators
CA3104298A1 (en) 2018-06-21 2019-12-26 Icahn School Of Medicine At Mount Sinai Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use
US10807959B2 (en) 2018-08-16 2020-10-20 Vanderbilt University WDR5-MLL1 inhibitors and modulators
CN109734674B (zh) 2019-02-26 2022-08-26 中国药科大学 苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途
WO2020179859A1 (ja) 2019-03-06 2020-09-10 第一三共株式会社 ピロロピラゾール誘導体
CN118908962A (zh) 2019-05-06 2024-11-08 西奈山伊坎医学院 作为hpk1的降解剂的异双功能化合物
CN111039860B (zh) * 2019-12-02 2022-09-13 河北科技大学 2-羟基-n-(4’-氯联苯-2-基)烟酰胺的合成方法及应用
CN113024538B (zh) * 2019-12-24 2022-09-09 南开大学 吡唑酰胺类化合物及其制备和在防治植物病菌病和杀虫中的应用
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
CN114539073A (zh) * 2022-02-18 2022-05-27 郑州萃智医药科技有限公司 3-溴-2-氯-4,6-二氟苯胺的合成方法
KR20250009417A (ko) * 2022-03-14 2025-01-17 후야바이오 인터내셔널, 엘엘씨 혈액-뇌 장벽 교차 mll1-wdr5 단백질-단백질 상호작용 저해제 화합물 및 이의 용도
EP4551560A4 (en) * 2022-03-14 2026-04-08 Huyabio Int Llc HALOALKYLPYRIDYLE TRIAZOLE PROTEIN-PROTEIN INTERACTION INHIBITOR MLL1-WDR5
AR129265A1 (es) 2022-05-12 2024-08-07 Syngenta Crop Protection Ag Compuestos de alcoxi-heteroaril-carboxamida o tioamida
WO2024002379A1 (zh) * 2022-07-01 2024-01-04 甘李药业股份有限公司 一种用作wdr5抑制剂的化合物或其可药用盐及其应用
WO2024015478A2 (en) * 2022-07-14 2024-01-18 Huyabio International, Llc Combination therapies of wdr5 inhibitors and pd-1 inhibitors
CN115974965B (zh) * 2022-08-31 2025-09-12 中国科学技术大学 一种靶向wdr5的多肽抑制剂及其用途
WO2026058961A1 (en) 2024-09-13 2026-03-19 Alivexis, Inc. Wdr5 inhibitors, compounds, pharmaceutical compositions, and methods of use thereof
CN119143715B (zh) * 2024-11-12 2025-03-14 天津匠新致成科技有限公司 二芳基团甲基哌嗪类化合物及其制备方法、药物组合物和应用
CN119661474A (zh) * 2024-12-16 2025-03-21 中国药科大学 一类羟肟酸类的双靶点化合物衍生物及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09505050A (ja) 1993-11-12 1997-05-20 ジ・アップジョン・カンパニー ピリミジン−チオアルキルおよびアルキルエーテル化合物
JPH0959236A (ja) 1995-08-23 1997-03-04 Dai Ichi Seiyaku Co Ltd ベンズアミド化合物
US20010051719A1 (en) 1996-12-19 2001-12-13 Smithkline Beecham P.L.C. Novel compounds
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
DE19952146A1 (de) 1999-10-29 2001-06-07 Boehringer Ingelheim Pharma Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP1274705A1 (en) 2000-03-29 2003-01-15 Cyclacel Limited 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
JP2002193938A (ja) 2000-12-01 2002-07-10 Bayer Ag 4−アリールピリジン誘導体
WO2002088101A2 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibitors of bace
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
KR20050029209A (ko) 2002-07-15 2005-03-24 미리어드 제네틱스, 인크. 화합물, 조성물 및 이의 사용방법
US7312341B2 (en) 2002-09-09 2007-12-25 Cgi Pharmaceuticals, Inc. 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof
GB0412072D0 (en) 2004-05-28 2004-06-30 Syngenta Participations Ag Chemical compounds
JP4688876B2 (ja) 2004-06-10 2011-05-25 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼ阻害剤としての化合物および組成物
RU2368602C2 (ru) 2005-01-26 2009-09-27 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназ
WO2006124731A2 (en) 2005-05-12 2006-11-23 Irm Llc Compounds and compositions as protein kinase inhibitors
DE102005022977A1 (de) 2005-05-19 2006-12-07 Merck Patent Gmbh Phenylchinazolinderivate
US20070254894A1 (en) 2006-01-10 2007-11-01 Kane John L Jr Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation
JP2009525978A (ja) 2006-02-06 2009-07-16 アイアールエム・リミテッド・ライアビリティ・カンパニー プロテインキナーゼ阻害剤としての化合物および組成物
EP2606890A1 (en) 2006-04-05 2013-06-26 Novartis AG Combinations comprising BCR-ABL/C-KIT/PDGF-R TK inhibitors for treating cancer
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
AU2008266290A1 (en) 2007-06-15 2008-12-24 Irm Llc Protein kinase inhibitors and methods for using thereof
CN101875617B (zh) 2009-03-23 2015-05-20 中国医学科学院药物研究所 烷氧基取代芳环的氨甲酰基类芳酸化合物及其制法和用途
CN102574830A (zh) 2009-05-07 2012-07-11 阿斯利康(瑞典)有限公司 取代的1-氰基乙基杂环基甲酰胺化合物750
EP2558085B1 (en) 2010-04-16 2017-08-30 Athenex, Inc. Compositions and methods for the prevention and treatment of cancer
WO2011149874A2 (en) * 2010-05-26 2011-12-01 Schering Corporation N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1
WO2011156557A2 (en) 2010-06-11 2011-12-15 Thomas James B Compounds active at the neurotensin receptor
CN103189067A (zh) * 2010-06-16 2013-07-03 密执安大学评议会 Wdr5与其结合配偶体的相互作用的抑制及治疗方法
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
TW201406736A (zh) * 2012-06-28 2014-02-16 Fujifilm Corp 新穎的醯胺衍生物或其鹽
WO2014048878A1 (en) 2012-09-26 2014-04-03 Evotec (Uk) Ltd. Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia
CN105051005B (zh) 2012-10-12 2017-06-13 武田药品工业株式会社 环丙胺化合物及其用途
EP2951170B1 (en) 2013-02-04 2018-10-24 Janssen Pharmaceutica NV Flap modulators
EP3079682A4 (en) 2013-12-13 2017-08-30 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
US9856223B2 (en) 2013-12-13 2018-01-02 Dana-Farber Cancer Institute, Inc. Methods to treat lymphoplasmacytic lymphoma
CN104926801B (zh) 2014-03-22 2019-06-04 浙江大学 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用
CN105585565B (zh) 2014-10-23 2019-10-01 中国医学科学院药物研究所 含2-苯胺基-4-噻唑基吡啶衍生物及其制法和药物组合物与用途
CN105837575B (zh) 2015-01-13 2019-01-15 四川大学 3-乙炔基吡唑并嘧啶衍生物及其制备方法和用途
CN105175284B (zh) 2015-07-21 2017-06-16 中国药科大学 酰胺类化合物、制备方法及其医药用途
CN116375797A (zh) 2016-03-01 2023-07-04 伊玛提克斯生物技术有限公司 用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物
CA3015417A1 (en) 2016-03-01 2017-09-08 Propellon Therapeutics Inc. Inhibitors of wdr5 protein-protein binding
JP7624690B2 (ja) 2016-03-01 2025-01-31 プロペロン セラピューティクス インコーポレイテッド Wdr5タンパク質-タンパク質結合の阻害剤
WO2017221092A1 (en) 2016-06-20 2017-12-28 Novartis Ag Triazolopyridine compounds and uses thereof
US10160763B2 (en) 2016-09-13 2018-12-25 Vanderbilt University WDR5 inhibitors and modulators
MX2020002399A (es) 2017-09-06 2020-07-22 Propellon Therapeutics Inc Inhibidores del enlace proteína-proteína de wdr5.
US10501466B2 (en) 2017-09-19 2019-12-10 Vanderbilt University WDR5 inhibitors and modulators
EP3870173A4 (en) 2018-10-24 2022-06-22 Vanderbilt University WDR5 INHIBITORS AND MODULATORS
WO2021026672A1 (en) 2019-08-09 2021-02-18 Novartis Ag Heterocyclic wdr5 inhibitors as anti-cancer compounds

Similar Documents

Publication Publication Date Title
JP2019512482A5 (https=)
HRP20251479T1 (hr) Pesticidno aktivni kondenzirani biciklički heteroaromatski spojevi
JP2010510319A5 (https=)
HRP20212000T1 (hr) Aminotriazolopiridini kao inhibitori kinaze
JP4638355B2 (ja) チアゾール誘導体
RU2017116598A (ru) Соединения и композиции для модуляции киназной активности мутантов egfr
JP2010533158A5 (https=)
JP2016523911A5 (https=)
RU2016102137A (ru) Первичные карбоксамиды в качестве ингибиторов bik
JP2014062093A5 (https=)
JP2016517878A5 (https=)
JP2019507179A5 (https=)
IL303196B1 (en) Heteroaryl substituted pyridines and methods of use
JP2010513444A5 (https=)
JP2016523976A5 (https=)
HRP20110520T1 (hr) Acilaminopirazoli kao inhibitori fgfr
RU2013143028A (ru) Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ
RU2019132212A (ru) Селективные ингибиторы hdac6
JP2017530999A5 (https=)
ME01507B (me) Imidazotriazini i imidazopirimidini kao inhibitori kinaze
RU2018131766A (ru) 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета
RU2009101911A (ru) Производные пиридина и пиразина в качестве ингибиторов mnk-киназы
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
JP2017530185A5 (https=)
RU2017120855A (ru) Замещенные аналоги мочевины с мостиковой связью в качестве модуляторов сиртуина